- External Partnership Management- Cross-Functional Collaboration- Project Management- Trend Analysis and Reporting- Open Innovation Process Development

- Motivated, coached, and managed a team of 10 employees to achieve performance targets- Automated KPI workflow resulting in improved productivity (90% time reduction)- Supported area manager by project managing health and safety issues in relation to COVID19

- Managed 4 employees in a team to implement statistical process control (SPC) as a QC method - Coordinated Training of over 100 employees using the method- Planned using agile project methods and coordinated with stakeholders

- Managing reduction of material loss at the production site- Planned, tested, and implemented green initiatives- Planned LEAN meetings supporting several project groups across several departments

Alumni organization supporting iGEM Stockholm

Medical device start-up focused on end-stage renal disease:- R&D for current portfolio and future products- Compiling scientific reports, experimental design, and 3D-printing prototypes

iGEM is a worldwide competition in the field of synthetic biology, initiated at MIT – Boston. iGEM stands for “International Genetically Engineered Machine”. It is a competition that aims to promote this field of biology and make it easier for anyone to be part of the future of living organisms. More than 5 000 students from all over the world strive towards a common goal - to put a research project from theory into practice.iGEM Stockholm 2017 aimed to develop a novel treatment with a self-regulated system residing in the lungs, capable of releasing enzymes to promote respiratory health by degrading excessively thick mucus. Our lung probiotic would safely reside in the lungs, sense the change in density of the excessively thickened mucus, and subsequently release mucus-degrading enzymes. The objective is to reduce the viscosity of mucus by removing glycans, aiming to restore the mucociliary clearance. Once the mucus has been restored, the release of enzymes will be inhibited. This mechanism ensures that our probiotic can be self-regulated. At the same time, the spread of bacteria is controlled by an integrated biocontainment system, ensuring that PROlung remains in the lungs without affecting the host’s lung microbiome.